Viral Infection Treatment Conjugates with Neuraminidase Inhibitors
Summary
US20260108618A1 covers compositions and methods for treating viral infections using conjugates containing neuraminidase inhibitors (zanamivir, peramivir, or analogs) linked to an Fc monomer, Fc domain, Fc-binding peptide, albumin protein, or albumin-binding peptide. The application was filed on July 23, 2025, under application number 19277976. Inventors include Allen Borchardt, Thomas P. Brady, Zhi-Yong Chen, Thanh Lam, and Leslie W. Tari. CPC classifications include A61K 47/68, A61K 47/6803, A61P 31/16, and C07D 309/28, indicating pharmaceutical and chemical therapeutic compositions.
“Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
US20260108618A1, published April 23, 2026, discloses pharmaceutical compositions and methods for treating viral infections, particularly influenza, using conjugates that combine neuraminidase inhibitors such as zanamivir or peramivir with an Fc monomer, Fc domain, Fc-binding peptide, albumin protein, or albumin-binding peptide. The filing (application number 19277976) names five inventors and covers both the conjugate compositions and methods of using them in therapy.
Entities monitoring the pharmaceutical IP landscape should note this application as it represents a potentially broad claim structure covering multiple neuraminidase inhibitor formats linked to antibody-related carrier proteins, which could have implications for competing therapeutic development programs in the antiviral space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
Application US20260108618A1 Kind: A1 Apr 23, 2026
Inventors
Allen BORCHARDT, Thomas P. BRADY, Zhi-Yong CHEN, Thanh LAM, Leslie W. TARI
Abstract
Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).
CPC Classifications
A61K 47/68 A61K 47/6803 A61P 31/16 C07D 309/28
Filing Date
2025-07-23
Application No.
19277976
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.